Analysts Set Expectations for RIGL Q3 Earnings

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) – Stock analysts at HC Wainwright issued their Q3 2026 earnings per share (EPS) estimates for Rigel Pharmaceuticals in a note issued to investors on Wednesday, March 4th. HC Wainwright analyst J. Pantginis forecasts that the biotechnology company will post earnings of $1.27 per share for the quarter. The consensus estimate for Rigel Pharmaceuticals’ current full-year earnings is $0.22 per share. HC Wainwright also issued estimates for Rigel Pharmaceuticals’ Q4 2026 earnings at $1.30 EPS and FY2026 earnings at $4.73 EPS.

Other research analysts also recently issued research reports about the stock. Citigroup restated a “buy” rating on shares of Rigel Pharmaceuticals in a research report on Wednesday, January 14th. Weiss Ratings restated a “hold (c+)” rating on shares of Rigel Pharmaceuticals in a report on Thursday, January 22nd. Zacks Research raised shares of Rigel Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Wednesday, February 18th. Finally, Wall Street Zen upgraded Rigel Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Sunday, December 21st. Three equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $45.67.

Rigel Pharmaceuticals Price Performance

Rigel Pharmaceuticals stock opened at $29.52 on Friday. The firm has a market cap of $545.23 million, a P/E ratio of 1.56 and a beta of 1.10. The stock’s 50 day moving average is $37.16 and its 200 day moving average is $37.32. The company has a debt-to-equity ratio of 0.06, a current ratio of 2.42 and a quick ratio of 2.14. Rigel Pharmaceuticals has a one year low of $15.50 and a one year high of $52.24.

Insider Transactions at Rigel Pharmaceuticals

In other Rigel Pharmaceuticals news, Director Walter H. Moos sold 4,000 shares of the firm’s stock in a transaction on Friday, February 20th. The shares were sold at an average price of $36.36, for a total value of $145,440.00. Following the completion of the sale, the director directly owned 12,722 shares in the company, valued at approximately $462,571.92. This trade represents a 23.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 9.48% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Rigel Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. AQR Capital Management LLC bought a new stake in Rigel Pharmaceuticals during the 1st quarter valued at $191,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Rigel Pharmaceuticals by 14.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 11,366 shares of the biotechnology company’s stock worth $204,000 after acquiring an additional 1,464 shares in the last quarter. Aviva PLC raised its holdings in shares of Rigel Pharmaceuticals by 16.0% in the 2nd quarter. Aviva PLC now owns 23,789 shares of the biotechnology company’s stock worth $446,000 after acquiring an additional 3,285 shares during the last quarter. Acadian Asset Management LLC lifted its position in Rigel Pharmaceuticals by 10.3% in the 2nd quarter. Acadian Asset Management LLC now owns 623,004 shares of the biotechnology company’s stock valued at $11,664,000 after acquiring an additional 57,959 shares in the last quarter. Finally, Geode Capital Management LLC lifted its holdings in shares of Rigel Pharmaceuticals by 1.1% in the second quarter. Geode Capital Management LLC now owns 415,607 shares of the biotechnology company’s stock valued at $7,786,000 after purchasing an additional 4,439 shares in the last quarter. Institutional investors own 66.23% of the company’s stock.

Key Headlines Impacting Rigel Pharmaceuticals

Here are the key news stories impacting Rigel Pharmaceuticals this week:

• Positive Sentiment: Q4 earnings/call showed record net income and management highlighted pipeline progress and new targets, supporting longer‑term growth prospects. Rigel Pharmaceuticals Inc (RIGL) Q4 2025 Earnings Call Highlights
• Neutral Sentiment: FY2026 revenue guidance was reiterated/updated to about $275M–$290M (vs. consensus ~$281.8M) — range overlaps consensus, so guidance is broadly in line but leaves room for volatility depending on contract revenue execution.
• Negative Sentiment: HC Wainwright trimmed its FY2027 and FY2028 EPS forecasts (FY27: from $3.92 to $3.85; FY28: from $4.73 to $4.42) and provided quarterly EPS projections, signaling tempered near‑term earnings expectations.
• Negative Sentiment: Analysts and coverage note risk to near‑term revenue: Seeking Alpha highlights falling contract revenue that could drive a revenue/earnings contraction, which likely pressured sentiment. Rigel Pharma stock slides as falling contract revenue to drive contraction
• Negative Sentiment: New disclosure flags FDA fast‑track ambitions carry significant regulatory uncertainty — adds execution risk for pipeline assets and could temper upside until clear regulatory paths are defined. Rigel Pharmaceuticals’ Fast Track Ambitions Face Significant FDA Uncertainty
• Negative Sentiment: Consensus analyst stance is “Hold,” reflecting mixed views on near‑term commercialization and revenue durability. Rigel Pharmaceuticals Receives Consensus Recommendation of “Hold”

About Rigel Pharmaceuticals

Rigel Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. Founded in 2003, Rigel focuses on the discovery, development and commercialization of novel small molecule therapeutics targeting immune, hematologic and oncologic diseases. Leveraging a proprietary chemistry platform and expertise in signal transduction pathways, the company aims to address significant unmet medical needs in both rare and common disorders.

Rigel’s lead product, fostamatinib (commercially known as Tavalisse®), is an oral spleen tyrosine kinase (SYK) inhibitor approved in the United States for the treatment of adult patients with chronic immune thrombocytopenia (ITP).